PHVS Stock Analysis: Pharvaris BV | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.190m USD | 12M Return: 41.2% | NL00150005Y4 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.7M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pharvaris N.V. is a late-stage biopharmaceutical company developing therapies for rare diseases, with a primary focus on angioedema and other bradykinin-mediated conditions. Its lead candidate, deucrictibant, is a small molecule bradykinin B2-receptor antagonist being evaluated in Phase 3 trials for the treatment and prophylaxis of hereditary angioedema (HAE) attacks, as well as for acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). The company is advancing both an extended-release tablet and an immediate-release capsule formulation of the drug.
Founded in 2015 and headquartered in Zug, Switzerland, Pharvaris operates in the biotechnology sub-sector of health care, where companies typically derive long-term value from clinical pipeline progression and eventual regulatory approvals. As a rare disease-focused biopharma, the company is positioned in a segment that often benefits from orphan drug regulatory pathways, which can provide extended market exclusivity upon approval.
- Deucrictibant Phase 3 HAE prophylaxis data readout approaches
- FDA approval pathway for deucrictibant HAE therapy advances
- Competition intensifies from Takeda, BioCryst, Ionis in HAE market
- Cash burn and potential equity raise risk persist pre-commercial
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.47 > 0.02 and ΔFCF/TA 17.94 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.47 > 3% & CFO -156.0m > Net Income -171.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.1m) vs 12m ago 24.47% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 326.9m - Total Current Liabilities 27.4m) / Total Assets 328.7m |
| B: -2.03 (Retained Earnings -668.6m / Total Assets 328.7m) |
| C: -0.65 (EBIT TTM -175.2m / Avg Total Assets 269.2m) |
| D: 10.80 (Book Value of Equity 300.8m / Total Liabilities 27.9m) |
| Altman-Z'' = 6.31 = AAA |
As of October 08, 2026, the stock is trading at USD 31.68 with a total of 341,841 shares traded. Over the past week, the price has changed by -0.13%, over one month by -16.28%, over three months by -8.41% and over the past year by +41.18%.
Current recommended Stop Loss: 27.50 (which is 13.2% or 2.6 ATR below the current price).
Pharvaris BV has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy PHVS.
- StrongBuy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 57.3 | 81% |
Market Cap EUR = 1.95b (2.19b USD * 0.89279997348785 USD.EUR)
P/B = 6.7395
Revenue TTM = 0.0 EUR
EBIT TTM = -175.2m EUR
EBITDA TTM = -174.7m EUR
Long Term Debt = 481k EUR (estimated: total debt 674k - short term 192k)
Short Term Debt = 192k EUR (from shortTermDebt, last quarter)
Debt = 674k EUR (from shortLongTermDebtTotal, last quarter) (leases 674k already included)
Net Debt = -317.6m EUR (calculated: Debt 674k - CCE 318.3m)
Enterprise Value = 1.64b EUR (1.95b + Debt 674k - CCE 318.3m)
Interest Coverage Ratio = unknown (Ebit TTM -175.2m / Interest Expense TTM 0.0)
EV/FCF = -10.49x (Enterprise Value 1.64b / FCF TTM -156.1m)
FCF Yield = -9.53% (FCF TTM -156.1m / Enterprise Value 1.64b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 4.98 (Enterprise Value 1.64b / Total Assets 328.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 674k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -138.4m (EBIT -175.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.94 (Total Current Assets 326.9m / Total Current Liabilities 27.4m)
Debt / Equity = 0.00 (Debt 674k / totalStockholderEquity, last quarter 300.8m)
Debt / EBITDA = 1.82 (negative EBITDA) (Net Debt -317.6m / EBITDA -174.7m)
Debt / FCF = 2.03 (negative FCF - burning cash) (Net Debt -317.6m / FCF TTM -156.1m)
Total Stockholder Equity = 280.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.72% (Net Income -171.6m / Total Assets 328.7m)
RoE = -61.24% (Net Income TTM -171.6m / Total Stockholder Equity 280.2m)
RoCE = -62.42% (EBIT -175.2m / Capital Employed (Equity 280.2m + L.T.Debt 481k))
RoIC = -45.91% (negative operating profit) (NOPAT -138.4m / Invested Capital 301.5m)
WACC = 8.05% (E(1.95b)/V(1.96b) * Re(8.05%) + D(674k)/V(1.96b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.34 | Cagr: 11.01%
[DCF] Fair Price = unknown (Cash Flow -156.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.79 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.72 | Chg30d=+0.58% | Revisions=-36% | Analysts=11
EPS current Year (2026-12-31): EPS=-2.77 | Chg30d=-0.11% | Revisions=-50% | GrowthEPS=+6.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.71 | Chg30d=-1.16% | Revisions=-36% | GrowthEPS=+2.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -47% (up=8, down=25)